Trusted Resource for Clinical Trials, Protocols & Progress
Regulation (EU) No 536/2014 — also known as the Clinical Trials Regulation (CTR) — harmonizes the assessment and supervision processes for clinical trials throughout the European Union. Replacing the previous Clinical Trials Directive (2001/20/EC), CTR introduces a centralized submission process via the Clinical Trials Information System (CTIS) and a coordinated review model for multinational trials.
Click to read the full article.
Clinical trial sponsors conducting studies across multiple regions often face the challenge of navigating distinct regulatory frameworks. In the United States, initiating a clinical trial requires filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). In the European Union, a Clinical Trial Application (CTA) must be submitted under the Clinical Trials Regulation (EU) No 536/2014 using the Clinical Trials Information System (CTIS).
Click to read the full article.
Ethics committees are critical to safeguarding the rights, safety, and well-being of participants in clinical research. Within the Clinical Trial Application (CTA) process under Regulation (EU) No 536/2014, ethics review is no longer separate from regulatory assessment but is instead embedded in the centralized workflow, specifically under Part II of the CTA.
Click to read the full article.
Conducting clinical trials across international markets requires sponsors to understand and navigate a complex patchwork of regulatory systems. Two primary models are widely used for initiating trials: the Clinical Trial Application (CTA) system and the Clinical Trial Notification (CTN) system. While both are designed to ensure safety and scientific rigor, they differ significantly in complexity, timelines, documentation, and regulatory oversight.
Click to read the full article.
Canada offers a well-defined regulatory pathway for sponsors seeking approval to conduct clinical trials involving pharmaceuticals, biologics, and natural health products. Managed by Health Canada under Division 5 of the Food and Drug Regulations, the Clinical Trial Application (CTA) is the formal mechanism through which sponsors submit requests for authorization to begin trials in humans.
Click to read the full article.
The Clinical Trials Information System (CTIS) is the centralized EU portal established under Regulation (EU) No 536/2014 to support the submission, assessment, and supervision of clinical trials throughout the European Union. It replaces the older EudraCT system and enables a single-entry point for all regulatory and ethics communications for multi-member state studies.
Click to read the full article.
Conducting clinical trials across the European Union involves more than regulatory filings—it requires careful attention to language and translation. Regulation (EU) No 536/2014 mandates that documents submitted for a Clinical Trial Application (CTA) must be understandable to local stakeholders, especially ethics committees and trial participants.
Click to read the full article.
Once a Clinical Trial Application (CTA) is approved and the study is initiated in the European Union, sponsors and investigators must fulfill strict safety reporting obligations as outlined in Regulation (EU) No 536/2014. These requirements aim to ensure timely detection and communication of potential risks to participants.
Click to read the full article.
Timely approval of a Clinical Trial Application (CTA) is critical for sponsors aiming to initiate clinical trials across European Union (EU) Member States. With the enforcement of Regulation (EU) No 536/2014 and the mandatory use of the Clinical Trials Information System (CTIS), the European Medicines Agency (EMA) has established uniform review timelines applicable across all EU countries.
Click to read the full article.
Clinical Trial Applications (CTAs) are essential to initiating clinical studies across jurisdictions. While each country or region has specific regulatory requirements, some common mistakes in filing CTA submissions consistently delay approvals or lead to outright rejections. Whether filing through the EU’s CTIS, Canada’s Clinical Trial Application process, or Asia-Pacific systems, ensuring alignment with local expectations is critical.
Click to read the full article.
